EXAS said on today’s CC that they’re spending significant money to induce trial centers in the DEEP-C study (http://www.clinicaltrials.gov/ct2/show/NCT01397747 ) to enroll more patients age 65 and up, which struck me as curious. Have other biotech companies reported paying trial centers for such an inducement?
Market Data 
Markets 
AI
